During the course of this presentation we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the FDA, the status and timing of ongoing research, corporate partnering activities and other factors affecting Adherex
Technologies’ financial condition or operations. Such forward looking statements are not guarantees of future performance and involve risk, uncertainties and other factors that may cause actual results, performance or achievements to vary materially from those expressed or implied in such statements. These and other risk factors are listed from time to time in reports filed with the SEDAR and the Securities and Exchange Commission, including but not limited to, reports on Forms 10-Q and 10-K. Adherex does not intend to update any forward looking information to reflect actual results or changes in the factors affecting forward-looking information.

Biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics
Two late stage oncology clinical products: Sodium Thiosulfate (STS) and
Eniluracil (EU)
STS: pending favorable data will file for NDA
EU: pending partnering discussions advance to Phase III
US based management team
Headquarters in Research Triangle Park, NC
Ticker: ADHXF – USA, AHX – Toronto
Market Cap: $10 MM; 25.1 MM shares outstanding
$1.0 MM in cash at 6/30/13, no debt
Large insider ownership with aligned shareholder incentives

Rosty Raykov – Chairman and CEO
Bear Stearns, Tiedemann Group, John Levin & Co., Alchem and DCML Co.
Chris Rallis – Director
30 years of business development, legal and operating experience at
Wellcome and Triangle Pharmaceuticals. Currently, executive in residence with Pappas Ventures.
Steve Skolsky – Director
30 years of operating experience, including Head of Glaxo Welllcome’s
Division of HIV/Oncology, Chief Executive at Trimeris and Sequoia
Pharmaceuticals. Currently, Global Head of Clinical and Data Operations at
Quintiles.

STS
STS is a chemo-protectant agent being developed exclusively in children to prevent hearing loss caused by cisplatin
Received Orphan Drug Designation in 2004 with 7.5 years exclusivity upon approval
Phase III trial conducted by Children’s Oncology Group is fully enrolled with data on 135 patients expected to be published first half 2014
Phase III trial conducted by SIOPEL6 in children with liver cancer 80/102 patients enrolled
Clinical trial costs covered by government grants
Adherex has exclusive rights to data from both studies
Potential for Rare Pediatric Disease Voucher: upon approval of STS
6 month priority review to any other new NDA or BLA application
Voucher can be transferred or sold with no restrictions
Intellectual property: Use-patent as chemo-protectant in-licensed from OHSU
Issued European and Japanese patents expire 2021, US pending prosecution

Platinum drugs are widely used anti cancer agents in pediatric oncology
Produce profound, irreversible, cumulative hearing loss
Destroy the cochlear hair cells of inner ear
Effect can be seen after as little as the second or third dose
Hearing loss (ototoxicity) is a dose-limiting side effect
Up to 2,000 children receive platinum based chemotherapy every year in the
US: 40-90% develop irreversible ototoxicity *
Loss of high frequency hearing sensitivity - loss of high frequency consonants (s/f/th/p/k/h/t)
Background noise compounds disability in critical settings - distance hearing and hearing in the classroom
Infants and young children at critical stage of development lack speech language development and literacy
Older children and adolescents lack social-emotional development and educational achievement
*Neuwelt and Brock. J Clin Oncol 2010;28:1630-1632

100
61% bilateral hearing loss
(ASHA criteria) at the end of treatment
90
80
70
88
75
41% required hearing aids that only partially restore hearing
60
50
40
67
50
22% of patients had dose reductions due to ototoxicity
20
10
N=67 age 8 m -20 years
30
0
Medulloblastoma Osteosarcoma Neuroblastoma PNET
*Gilmer-Knight et al., Journal of
Clinical Oncology
11
Germ cell

Hearing Loss
Detected or
Communicated by Patient
Hearing Loss Diagnosed
Detectable hearing loss generally begins after about two or three cycles of cisplatin, and may continue to occur for months (or longer) after use is discontinued
Continue Course
Leads to more severe hearing loss
Dose Modify Switch therapies
Less effective dosing/treatment, potentially shortening survival

Antitumor Effect
NH
3
Pt
Cl
NH
3
Cl
Ototoxicity Effect
NH
3
Pt
Protein
Cl
NH
3
STS
Cl
NH
3
NH
3
Pt
Protein
Cl
Cl
Requires both Cl unbound to crosslink DNA
Binding to plasma proteins occurs within first hour which inactivates one binding site
Free cDDP (unbound) short t
1/2
:1.5 hr
Requires one Cl unbound to affect cochlear hair cells
Binding to plasma proteins occurs within first hour which inactivates one binding site
STS will bind second site preventing ototoxicity

Change from baseline hearing threshold. Effect of STS
(8 g/m2 IV) 4 hrs, 8 hrs, or 12 hrs after administration of cisplatin (6 mg/kg IA)
Delayed administration of STS after platinum agents in animals reduces ototoxicity
*Dickey DT et al. J Pharmacol Exp Therapeut 2005;314:1052-1058

Cisplatin clearance is complete by 6 hrs with or without STS, when STS levels are at or higher than clinically achievable levels
Cisplatin Pharmacokinetics nu/nu mice administered 4 mg/kg CDDP i.p.
STS Pharmacokinetics nu/nu mice administered 3.5 g/kg STS i.p.
Mouse # 1
Mouse # 2
Mouse # 3
Mouse # 4
Mouse # 5
Mouse # 6
1 min
222.0 mg/dL
STS Level
15 min
941.0 mg/dL
180.0 mg/dL
133.5 mg/dL
5.85 mg/dL n/a
145.8 mg/dL not detectable
177.1 mg/dL
1131.0 mg/dL
1246.0 mg/dL
975.0 mg/dL
*Gregory Reaman et al

STS allows for anti-tumor activity when given properly
*Harned TM et al. Clin Cancer Res 2008;14:533-540

COG ACCL0431:
Newly diagnosed children with hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma
Study Chair: David Freyer, DO, MS
135 randomized patients fully enrolled and study completed in
1Q 2012
Futility analysis conducted and reviewed by COG DSMC August 2011 with recommendation at the time to continue study
Expect data to be published first half 2014

COG ACCL0431:
Note: Patient must first be enrolled on the COG hearing assessment study, ACCL05C1
Diagnosis
Newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, or osteocarcoma
Planned treatment program includes  200 mg/m 2 cisplatin
(administered according to the disease-specific regimen)
Audiology done with each cycle of therapy
80% power to detect
22.5% vs 45% change in hearing
Study entry onto ACCL0431
Randomization
Sodium thiosulfate given intravenously over
15 minutes starting 6 hours after completion of each cisplatin infusion (STS Arm)
No sodium thiosulfate treatment given (Observation Arm)
80% power to rule out
>12% difference in
3 yr EFS
Secondary objectives measurement of nephrotoxicity and neurotoxicity
Protocol therapy ends when patient completes planned treatment regimen containing cisplatin

SIOPEL 6:
Newly diagnosed children with standard risk hepatoblastoma
Study Chair: Peppy Brock, MD
80 randomized patients fully enrolled out of 102
Interim evaluations of efficacy of the chemotherapy carried out and reviewed by IDMC after 20, 40, 60 and 80 patients are evaluable for response
Early stopping will be considered in case of concerns on efficacy of chemotherapy in either treatment arm
The first two interim safety analysis after 20 and 40 patients were conducted with
IDMC recommending study to continue
Two interim and one final efficacy analyses planned for early stopping in case of a greater than expected difference between treatment arms in terms of hearing loss

SIOPEL 6:
Diagnostic biopsy
Tumour storage
Radiological staging
RRR if required
Registration to remote data entry site via web
O
N
T
I
I
S
A
D
O
M
R
A
N cDDP 80 mg/m 2
4 Cycles cDDP 80 mg/m 2
STS: 10-20 gm/m 2 depending on age/weight
4 Cycles
R
G
S
U
E
R
Y
L
A
D
E
Y
E
D cDDP
2 Cycles cDDP + STS
2 Cycles
80% power to detect 60% vs 35% hearing loss
Two interim and one final efficacy analyses planned for early stopping in case of a greater than expected difference between treatment arms in terms of hearing loss

Event
FDA Type C Clinical Development Meeting 
Presented to Pediatric ODAC 
ODAC recognized challenge of demonstrating STS does not reduce efficacy of cisplatin and agreed adult study would not be appropriate
COG ACCL0431 Clinical Data Published
SIOPEL 6 Interim Efficacy Analysis
FDA Type C Clinical Meeting – Agree Data Acceptable for NDA
FDA Pre NDA Meeting
NDA Submission
Timing
Mar 2011
Nov 2011
H1 2014
H1 2014
H1 2014 mid 2014
1Q 2015

Pediatric Market Opportunity
12,000 children develop cancer in the US every year
2,000 children will receive platinum-based chemotherapy, 3x ROW
Pricing to be determined based on available therapies in the market
Competitive Position
Significance of injury increases value of STS
Limited competition – hearing aids and cochlear implants do not prevent hearing loss
Hearing aids cost $2000 to $6000 each
Cochlear implants cost up to $75,000 each
Third party market research shows strong adoption characteristics*
Physician approval very high
Payors feedback positive
*Campbell Alliance and Panel Intelligence market research, analysis and surveys

STS has Two Potential Near Term Value Drivers
Positive data from COG Phase III trial will support filing of NDA
Upon approval of NDA, receipt of Rare Pediatric Disease Voucher
Attractive Commercial Market Opportiunity
2,000 patients in the US (3x ROW), limited competition
Third party market research shows potential for strong adoption
Eniluracil is active and well tolerated
Indications where 5-FU is administered potentially in excess of $1
BLN market
Seek partnership for further development of Eniluracil